Zacks Investment Research Lowers Argos Therapeutics Inc. (ARGS) to Hold
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
ARGS has been the subject of several other research reports. Piper Jaffray Cos. restated an overweight rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Monday, June 20th. FBR & Co restated a buy rating on shares of Argos Therapeutics in a report on Tuesday, June 14th. Finally, Needham & Company LLC restated a buy rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Friday, June 17th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Argos Therapeutics has a consensus rating of Buy and a consensus price target of $11.50.
Shares of Argos Therapeutics (NASDAQ:ARGS) opened at 4.52 on Tuesday. The stock has a 50 day moving average price of $4.89 and a 200 day moving average price of $5.90. The firm’s market cap is $186.21 million. Argos Therapeutics has a 12-month low of $1.61 and a 12-month high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities analysts expect that Argos Therapeutics will post ($1.56) earnings per share for the current year.
In other Argos Therapeutics news, major shareholder International S. Pharmstandard acquired 75,474 shares of the business’s stock in a transaction on Monday, August 22nd. The shares were acquired at an average price of $4.24 per share, with a total value of $320,009.76. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder International S. Pharmstandard acquired 16,977 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was acquired at an average cost of $4.78 per share, for a total transaction of $81,150.06. The disclosure for this purchase can be found here. Corporate insiders own 61.64% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 3,559 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 33,862 shares in the last quarter. California State Teachers Retirement System acquired a new position in Argos Therapeutics during the second quarter valued at $137,000. Oxford Asset Management acquired a new position in Argos Therapeutics during the second quarter valued at $353,000. Finally, Vanguard Group Inc. boosted its position in shares of Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock worth $2,314,000 after buying an additional 137,390 shares in the last quarter. 11.05% of the stock is currently owned by institutional investors and hedge funds.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.